Moderna, IncNasdaq: MRNA
Health Care · Biotechnology
$62.15
+12.18%
Vol: 9.8M
Research Digest
Wednesday, June 17, 2026
Moderna announced an operating-model restructuring and a new Chief Commercial Officer while shares rallied ahead of a pivotal June 18 FDA advisory vote on its mRNA flu vaccine.
On June 16, 2026, Moderna announced changes to its operating model to prepare for up to three new product launches in 2027 and 2028, including a flu-plus-COVID combination, seasonal flu and norovirus vaccines, sending shares up about 3.5% to roughly $53.97. As part of the reorganization, Ester Banque was named Chief Commercial Officer effective June 15, 2026, to lead launch execution across three commercial franchises spanning infectious diseases, intismeran and rare diseases. Separately, sentiment was boosted after the FDA released briefing documents ahead of the June 18 VRBPAC advisory committee meeting on its mRNA seasonal flu vaccine mFlusiva; the documents noted some evidence gaps in older and immunocompromised populations but found no major deficiencies, which analysts read as a favorable setup, with shares having jumped about 9.1% on the news. This matters because a positive panel vote could expand Moderna's respiratory franchise as core COVID revenue declines. The risk is an unfavorable advisory outcome or lingering doubts in vulnerable populations, against a backdrop of a 34.3% sales decline.
Previous Market Intelligence
13 daysJun 16Moderna disclosed a Form 144 filing for a proposed insider sale of 53,336 shares via stock option exercise dated June 15, 2026.Neutral▶
On June 15, 2026, a Form 144 was filed disclosing a proposed sale of 53,336 shares of Moderna common stock, described as a stock option exercise. This is a routine insider transaction filing rather than a fundamental business catalyst, and on its own it does not change the investment thesis. The stock trades near $52 with a market cap around $20.7B, well off its 52-week high of $59.55 against a low of $22.28. Moderna remains under pressure from a sharp year-over-year sales decline as COVID and respiratory vaccine demand normalizes, while it pivots toward oncology and other mRNA programs. The bear case is continued revenue erosion and ongoing cash burn before the pipeline (cancer and latent-virus vaccines) can offset declining legacy product sales. The insider sale, while small relative to the float, can be read as a mild sentiment negative.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Moderna publishes positive Phase 3 flu vaccine data in NEJM; insider sells $2.58M ahead of pipeline catalystsMixed▶
On May 6, Moderna announced NEJM publication of positive Phase 3 results for mRNA-1010 seasonal flu vaccine, achieving 26.6% relative vaccine efficacy in adults 50+. Q1 results (May 1) outlined plans for up to 10% revenue growth in 2026 along with GAAP opex reductions. Moderna received European approvals for mNEXSPIKE, mCOMBRIAX (world first flu+COVID combo), and mRESVIA for all individuals. A new Phase 3 monotherapy trial for intismeran in Stage 1 NSCLC was started, plus Phase 3 of mRNA-1018 pandemic flu with CEPI. President Stephen Hoge sold 53,336 shares for $2.58M on May 15 under a Rule 10b5-1 plan. Average analyst PT is $43.37 with Hold consensus. Risk: stock trades on outbreak headlines (hantavirus) rather than commercial fundamentals; demand for COVID vaccines continues declining.
May 20Moderna's mRNA-1010 flu vaccine shows positive Phase 3 data in NEJM while Vertex discontinues CF mRNA partnershipMixed▶
On May 6, 2026, Moderna announced NEJM publication of positive Phase 3 data for its mRNA-1010 seasonal flu vaccine, showing rVE of 26.6% versus a standard-dose comparator in adults 50+. Shares climbed nearly 9% in premarket on May 11 amid hantavirus treatment exploration interest, though analysts viewed the market as structurally small. Moderna was ranked No. 1 on TIME's 2026 list of World's Most Impactful Companies on May 12. President Stephen Hoge sold 53,336 shares on May 15 for ~$2.58M. Bear case: Vertex discontinued its Phase 1/2 inhaled CFTR mRNA study (VX-522), removing a partnership data point, and the 23-analyst consensus remains Hold given ongoing losses and valuation concerns.
May 19No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 18Moderna shares climbed ~9% premarket May 11 on hantavirus therapy interest; Q1 2026 swung to $169.7M profit and TIME named it #1 Most Impactful CompanyPositive▶
Moderna delivered a strong Q1 2026, swinging to a $169.7M GAAP profit and reiterating plans for up to 10% revenue growth and GAAP opex reductions in 2026. The company received EU approval of mCOMBRIAX, the world's first flu/COVID combo vaccine, and initiated Phase 3 trials for intismeran in Stage 1 NSCLC and mRNA-1018 pandemic flu with CEPI. Shares jumped ~9% premarket on May 11 as investors weighed hantavirus therapy potential, though Evercore noted it is a low-incidence, structurally small market. The stock is up 58.91% YTD trading at $48.57 on May 17. NEJM published Phase 3 efficacy data for seasonal flu vaccine mRNA-1010. Average analyst rating is Hold with a 12-month PT of $36.82.
May 15Moderna Q1 2026 revenue jumped to $389M tripling YoY with NEJM publication of Phase 3 flu vaccine data and EU approval of mCOMBRIAX flu/COVID comboPositive▶
Moderna (MRNA) reported Q1 2026 revenue of $389M, more than tripling year over year and well above the $236M Street view, while the headline $1.3B GAAP net loss was largely driven by a $0.9B non-recurring litigation settlement charge. On May 6, 2026 the company announced an NEJM publication of pivotal Phase 3 clinical safety and efficacy data for its investigational seasonal influenza vaccine mRNA-1010 showing superior efficacy versus standard flu shot. Moderna received two European approvals including the world's first flu plus COVID combination vaccine, mCOMBRIAX. The company started a new pivotal trial for intismeran—its first Phase 3 monotherapy study for high-risk Stage 1 non-small cell lung cancer. Shares surged ~9% premarket on May 11, 2026 following hantavirus headlines after Moderna confirmed it had partnered with USAMRIID on early-stage hantavirus vaccine research, though Evercore noted limited commercial implications. Moderna was ranked no. 1 on TIME's 2026 World's Most Impactful Companies list and reiterated up to 10% revenue growth and GAAP opex cuts in 2026.
May 14Moderna jumps 16% on May 10 after Q1 revenue tripled to $389M and Phase 3 flu vaccine beats standard shotPositive▶
Moderna stock surged 16% on May 10 after Q1 revenue of $389M nearly tripled YoY and crushed the $236.4M consensus, though a $0.9B litigation charge drove a $1.3B GAAP loss. Phase 3 mRNA-1010 flu vaccine showed 26.6% relative efficacy vs standard-dose; FDA decision expected by August 5. EU approved mCOMBRIAX flu+COVID combo vaccine. Hantavirus vaccine Phase 1 data and outbreak headlines fueled an additional ~9% premarket pop on May 11. Cash position ~$5.2B with $4.5-5.0B targeted at year-end. Risk: Moderna and Merck halted a key skin cancer mRNA trial; high retail-driven volatility.
May 13Moderna stock jumped 16% on May 10 after Q1 revenue of $389M tripled YoY and positive Phase 1 hantavirus vaccine data; mRNA-1010 flu vaccine has PDUFA date August 5, 2026.Positive▶
Moderna stock surged 16% on May 10, 2026 after Q1 2026 revenue of $389M roughly tripled YoY and beat the FactSet consensus of $236.4M. On May 11, hantavirus cases sparked a surge in MRNA shares after positive Phase 1 vaccine data showed strong immune responses. The company published positive Phase 3 NEJM data May 6 for flu vaccine mRNA-1010 showing 26.6% relative vaccine efficacy in adults 50+, with FDA PDUFA goal date of August 5, 2026. Moderna ranked #1 on TIME's 2026 World's Most Impactful Companies list. The company agreed to pay Arbutus/Genevant up to $2.25B to settle lipid nanoparticle patent litigation. Stock is up 76.6% YTD.
May 12Moderna shares jumped 16% on May 9 and 8.1% on May 11 on hantavirus vaccine research disclosure plus Q1 revenue beat ($389M vs $236M expected), though $1.3B GAAP loss was inflated by $0.9B litigation settlement.Positive▶
Moderna delivered Q1 2026 revenue of $389M (more than triple YoY, beating $236M consensus) but reported a $1.3B GAAP net loss driven by a $0.9B one-time litigation settlement. Shares surged 16.03% on May 9 and another 8.1% on May 11 after the company disclosed early-stage hantavirus vaccine research with the U.S. Army Medical Research Institute, coinciding with a Yosemite cruise ship outbreak. The company received two European approvals including mCOMBRIAX (world's first flu+COVID combo vaccine) and started a Phase 3 study of intismeran in Stage 1 NSCLC. FY26 guidance reiterated for up to 10% revenue growth with R&D ~$3B. As of May 12, stock traded $51-$60 range. Risk: Evercore analysts caution that outbreak headline gains may not translate to meaningful revenue.
May 11Moderna shares jumped ~16% May 10 on Phase 3 flu vaccine superiority data published in NEJM and positive Phase 1 hantavirus readout.Positive▶
Moderna shares surged 16.03% May 10, 2026 after the company's Phase 3 P304 data for mRNA-1010 seasonal flu vaccine were published in the New England Journal of Medicine — showing 26.6% relative vaccine efficacy versus a licensed standard-dose vaccine in adults 50+. Regulatory reviews are underway in the U.S., Europe, Canada and Australia with a U.S. PDUFA goal date of August 5, 2026. The company also disclosed positive Phase 1 data for a hantavirus vaccine candidate. Q1 2026 revenue jumped to $389M vs. ~$236.4M consensus, though a $0.9B one-time litigation charge produced a $1.3B GAAP net loss. Year-end 2026 cash guided to $4.5–$5.0B from current ~$5.2B. Moderna and Merck terminated/restructured a Phase 2/3 mRNA-4157 skin squamous cell carcinoma trial.
May 8Moderna mRNA flu vaccine beat standard shots in Phase 3 trial; EU approved combo COVID/flu vaccine mCombriax; FDA decision expected by August 5.Positive▶
Moderna reported Q1 sales exceeding expectations with strong international vaccine revenue growth. New England Journal of Medicine published Phase 3 data showing Moderna mRNA-1010 flu vaccine outperformed standard flu shots. EU approved mCombriax (mRNA-1083), the company first combination COVID-19/influenza vaccine. MRNA-4359 plus Keytruda granted FDA fast track for unresectable/metastatic melanoma. Stock climbed 10% on hantavirus vaccine Phase 1 data showing strong immune responses. Skin cancer trial results expected in 2026. Risk: regulatory timelines and competitive vaccine landscape.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| MRNAMODERNA | $62.15 | +12.18% | +35.2% | -14.7x | 1.03 | $24.5B |
| ABBVABBVIE | $221.50 | -0.44% | +3.5% | 13.6x | 0.31 | $390.9B |
| AMGNAMGEN | $341.45 | -1.84% | +3.3% | 14.6x | 0.42 | $184.4B |
| GILDGILEAD | $125.32 | -1.50% | -3.9% | 13.0x | 0.33 | $155.8B |
| VRTXVERTEX | $458.94 | +1.27% | +5.7% | 21.4x | 0.31 | $116.5B |
| REGNREGENERON | $607.24 | -1.22% | -3.5% | 11.3x | 0.24 | $63.7B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.